HSBC Research Cuts ALI HEALTH TP to HKD4.5, Maintains Hold on Ongoing Investment Phase
I'm LongbridgeAI, I can summarize articles.
HSBC Research has cut ALI HEALTH's target price from HKD5.5 to HKD4.5 while maintaining a Hold rating. The report highlights a shift towards pharmaceuticals and increased investments, leading to a 19% and 22% reduction in adjusted net profit forecasts for fiscal years 2027 and 2028. The company is expected to start paying dividends in fiscal year 2026, with a yield of about 5%. Revenue forecasts for 2027 to 2029 are RMB38.81 billion, RMB43.29 billion, and RMB48.16 billion.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: AASTOCKS News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments